

November 20, 2013



ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe

Actions Filed in Germany to Stop Patent Infringement on Devices and Masks

DUSSELDORF, Germany, Nov. 20, 2013 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has won preliminary injunctions in Germany against several patent infringing activities by Taiwanese medical device manufacturer APEX Medical Corp. (APEX) and Chinese medical device manufacturer BMC Medical Co., Ltd. (BMC). The initial orders, entered by the Munich District Court, prohibit APEX and BMC from selling or marketing certain products in Germany without a further court order. Those products are:

- The APEX WiZARD 210 and WiZARD 220 mask headgear
- BMC's RESmart CPAP devices
- BMC's Willow/FeaLite nasal pillows patient interface

ResMed has also filed patent infringement lawsuits in Munich, Germany, seeking damages and permanent injunctions to stop infringement of ResMed patents by the products listed above, as well as the additional products below:

- The APEX iCH and XT Fit CPAP devices
- The APEX WiZARD 210 and WiZARD 220 masks

Earlier this year, ResMed pursued similar legal actions against APEX and BMC in the United States with the International Trade Commission (ITC). The U.S. government investigation started at ResMed's request against APEX resulted in an ITC consent decree against APEX stopping the importation and sale of infringing APEX products. Proceedings against BMC are ongoing.

"ResMed has a global business built on its investment in research and development, resulting in products that excel in performance, quality and comfort," said David Pendarvis, ResMed global general counsel and chief administrative officer. "We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists."

About ResMed:

ResMed is a global leader in the development, manufacturing and marketing of medical

products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

(Logo: <https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

Contacts:

For News Media

Gretchen Griswold

Director, Global Corporate Communications

O: 858-836-6789

news@resmed.com

For the Investor Community

Constance Bienfait

Director, Investor Relations

O: 858-836-5971

constance.bienfait@resmed.com

SOURCE ResMed Inc.